Hold the Obituary
Research into anticancer vaccines is moving forward on several fronts.
Experts Discuss New Diagnostic and Management Approaches in Multiple Myeloma
With the advent of safer and more effective treatments, early diagnosis of multiple myeloma (MM) has become an important goal.
Cancer Vaccine Field Remains Lively Despite Setbacks: 10+ Agents in Advanced Testing
The only therapeutic cancer vaccine ever to win approval from the FDA has repeatedly missed sales projections, plunging the company that developed it into bankruptcy proceedings.
SABCS Studies Highlight Promise and Complexity in Targeting PI3K in Breast Cancer
Although there is a significant scientific rationale for targeting the PI3K pathway in breast cancer, research findings presented recently at the 2014 San Antonio Breast Cancer Symposium (SABCS) highlight the inherent complexities in using agents directed at this cell-signaling network.
PD-1 Researchers Excited About Prospects for Checkpoint Strategy in Hodgkin Lymphoma
Amid continuing excitement over the potential for PD-1 pathway immune checkpoint blockade strategies in anticancer therapies, research presented at the 2014 American Society of Hematology (ASH) Annual Meeting helped established a foundation for the use of anti- PD-1/PD-L1 agents in hematologic malignancies.
Molecular Diagnostics in CML Illustrate Ways to Enhance Well-Established Strategies
Although there clearly are a number of worthy candidates for the single most influential event that unequivocally proclaimed the beginning of the modern era of precision cancer medicine, there would surely be many votes for the impact of imatinib on the course of the natural history of chronic myeloid leukemia.
Targeted Therapies and Immunotherapies Are Transforming Outcomes in Advanced NSCLC
Ten or 15 years ago, a diagnosis of advanced nonâ€“ small cell lung cancer (NSCLC) led directly to a discussion of chemotherapy.
Success Fuels Perez's Dreams of Helping Patients With Breast Cancer
Coping with challenges is part of the human condition, but self-awareness can have far-reaching results. Just ask Edith A. Perez, MD, about her experience attending medical school.
Novel VIL Approach Reduces Complications From Regional Lymphadenectomy in Melanoma
Surgical intervention is a Machiavellian endeavor: the ends justify the means. This obligates the clinician to minimize the risk of a procedure to justify the gains obtained from an intervention.
Sotigalimab/Pembrolizumab Combo Continues to Show Clinical Activity in Frontline Melanoma
Dr. Halmos on Trastuzumab Deruxtecan in NSCLC
Dr. Kris on Immunotherapy in NSCLC Without Driver Mutations
Checkpoint Inhibitor Challenges Warrant Consideration for a Targeted Approach in NSCLC
2 Clarke DriveSuite 100Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.